Targeting of the tumor antigen together with αGalCer to cDC1s via a Clec9α-coated nanoparticle vaccine strongly induced the expansion of antigen-specific CD8 T cells ex vivo from melanoma patients (46) and promoted the antitumor responses in vivo in humanized mice (47). This evidence concerns the gene CLEC9A and melanoma.